JP7451485B2 - 癌の予防または治療に使用するための化合物 - Google Patents

癌の予防または治療に使用するための化合物 Download PDF

Info

Publication number
JP7451485B2
JP7451485B2 JP2021500159A JP2021500159A JP7451485B2 JP 7451485 B2 JP7451485 B2 JP 7451485B2 JP 2021500159 A JP2021500159 A JP 2021500159A JP 2021500159 A JP2021500159 A JP 2021500159A JP 7451485 B2 JP7451485 B2 JP 7451485B2
Authority
JP
Japan
Prior art keywords
optionally substituted
cancer
ether
biphenyl
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021500159A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020002701A5 (enExample
JP2021530472A (ja
Inventor
ホセプ、ロマ、カスタニエール
マルタ、パスクアル、ヒラベルト
ホセ、サンチェス、デ、トレド、コディナ
ソレダド、ガジェゴ、メルコン
パトリシア、サルソサ、マルティネス
ハビエル、アロンソ、フェルナンデス
セルジオ、ペレス、オスカリス
クリスティーナ、ロペス、ゴメス
ホセプ、カステルス、ボリアルト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Universitari de Ciencia i Tecnologia
Original Assignee
Institut Universitari de Ciencia i Tecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Universitari de Ciencia i Tecnologia filed Critical Institut Universitari de Ciencia i Tecnologia
Publication of JP2021530472A publication Critical patent/JP2021530472A/ja
Publication of JPWO2020002701A5 publication Critical patent/JPWO2020002701A5/ja
Application granted granted Critical
Publication of JP7451485B2 publication Critical patent/JP7451485B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021500159A 2018-06-29 2019-07-01 癌の予防または治療に使用するための化合物 Active JP7451485B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18382485.3 2018-06-29
EP18382485.3A EP3586847A1 (en) 2018-06-29 2018-06-29 Compounds for use in preventing or treating cancer
PCT/EP2019/067557 WO2020002701A1 (en) 2018-06-29 2019-07-01 Compounds for use in preventing or treating cancer

Publications (3)

Publication Number Publication Date
JP2021530472A JP2021530472A (ja) 2021-11-11
JPWO2020002701A5 JPWO2020002701A5 (enExample) 2022-07-11
JP7451485B2 true JP7451485B2 (ja) 2024-03-18

Family

ID=62842045

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021500159A Active JP7451485B2 (ja) 2018-06-29 2019-07-01 癌の予防または治療に使用するための化合物

Country Status (6)

Country Link
US (1) US12006311B2 (enExample)
EP (2) EP3586847A1 (enExample)
JP (1) JP7451485B2 (enExample)
ES (1) ES2938412T3 (enExample)
PT (1) PT3813832T (enExample)
WO (1) WO2020002701A1 (enExample)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183324A1 (en) 2000-11-06 2002-12-05 Jacobson Irina C. Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
US20040006062A1 (en) 2002-05-06 2004-01-08 Smallheer Joanne M. Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183324A1 (en) 2000-11-06 2002-12-05 Jacobson Irina C. Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
US20040006062A1 (en) 2002-05-06 2004-01-08 Smallheer Joanne M. Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Sulfonamidolactam inhibitors of coagulation factor Xa，Bioorganic & Medicinal Chemistry Letters，2008年，18，pp.2428-2433，doi:10.1016/j.bmcl.2008.02.054

Also Published As

Publication number Publication date
EP3813832B1 (en) 2022-11-09
US20210230150A1 (en) 2021-07-29
PT3813832T (pt) 2023-02-03
ES2938412T3 (es) 2023-04-10
EP3813832A1 (en) 2021-05-05
US12006311B2 (en) 2024-06-11
JP2021530472A (ja) 2021-11-11
WO2020002701A1 (en) 2020-01-02
EP3586847A1 (en) 2020-01-01

Similar Documents

Publication Publication Date Title
JP6869947B2 (ja) 置換キナゾリン化合物ならびにそのｇ１２ｃ変異ｋｒａｓ、ｈｒａｓおよび／またはｎｒａｓタンパク質の阻害剤としての使用
JP7121660B2 (ja) 癌を処置するためのｅｚｈ２阻害剤の使用
JP5793428B2 (ja) プロドラッグ形態のキナーゼインヒビターおよび治療におけるそれらの使用
TW202039490A (zh) Mat2a之雜雙環抑制劑及用於治療癌症之使用方法
CN114364677B (zh) 作为toll-样受体激动剂的咪唑并[4,5-c]吡啶衍生物
JP2022545005A (ja) Ｋｒａｓ関連がんを治療する方法
JP2017518334A (ja) リンパ腫を治療するためのｅｚｈ２阻害剤
JP6612857B2 (ja) ベンゾイミダゾールアナログおよび関連方法
JP2023095928A (ja) 癌を処置するためのｅｚｈ２阻害剤の使用
KR20070043996A (ko) Ｃｈｋ1의 억제에 유용한 화합물
KR102864783B1 (ko) 피라졸로피리다지논 화합물, 그의 약학적 조성물 및 그의 용도
EP3212650B1 (en) Administration of ubiquitin-activating enzyme inhibitor and chemotherapeutic agents
US20170298020A1 (en) Methods and compounds for treating proliferative disorders and viral infections
AU2022243600A1 (en) Alk-5 inhibitors and uses thereof
TW201300105A (zh) 治療頭頸鱗狀細胞癌之相乘藥物組合物
CN108026046A (zh) 取代的喹唑啉化合物及其作为g12c突变体kras、hras和/或nras蛋白质的抑制剂的用途
WO2014194250A2 (en) Novel nanocarrier delivered cancer chemotherapeutic agents
CN120097859A (zh) Nurr1受体调节剂
JP7451485B2 (ja) 癌の予防または治療に使用するための化合物
KR20200104336A (ko) 수용체 티로신 키나제 억제제의 Tyro3, Axl 및 Mertk (TAM) 패밀리로서의 헤테로고리 화합물
CN107141287B (zh) 2-亚胺-5-酮基-2,5-二氢-1-h-二吡啶并嘧啶类化合物
KR102578288B1 (ko) 피라졸로피리다진 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
CN107056754B (zh) 内嵌脲类结构的wnt通路抑制剂
JP2021531253A (ja) Ｍｙｃ阻害のための改良された化合物
WO2024159088A1 (en) Compounds and methods for yap/tead modulation and indications therefor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220701

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220701

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231010

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240209

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240306

R150 Certificate of patent or registration of utility model

Ref document number: 7451485

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350